IDEXX Laboratories Appoints Jay Hooley to Board

By Ahmed Jameison • Thursday, July 10 10:15 • Permanent Link

IDEXX Laboratories, Inc. (NASDAQ: IDXX) has announced the election of Joseph L. (Jay) Hooley to the company's board of directors, effective July 10, 2025. Jay Hooley, the former chair and CEO of State Street Corporation, brings extensive strategic thinking and financial leadership experience to the board.

With the addition of Mr. Hooley, the IDEXX board of directors now comprises ten directors, nine of whom are independent. Lawrence D. Kingsley, the company's independent non-executive board chair, expressed excitement in welcoming Jay to the board, noting his substantial public company board and corporate governance experience.

Mr. Hooley, who currently serves on the board of directors of Exxon Mobil Corporation and Aptiv PLC, is expected to provide valuable insights that will contribute to the board’s overall effectiveness. His unique background and skills complement those of the other board members, and the company is confident that he will support IDEXX’s mission to advance the standard of care for pets and deliver on its purpose.

IDEXX Laboratories, Inc. is a global leader in pet healthcare innovation, offering diagnostic and software products and services that create clarity in the complex world of veterinary medicine. The company aims to support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community make confident decisions. IDEXX Laboratories, Inc. is a member of the S&P 500® index and employs approximately 11,000 people, offering solutions and products to customers in more than 175 countries and territories. Following these announcements, the company's shares moved 0.34%, and are now trading at a price of $540.64. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.